Project description
New software to diagnose cancer
Cancer diagnosis and prognosis is a health priority. Advances in cancer treatment, particularly precision medicine, show that personalised treatment programmes can significantly improve survival rates and treatment outcomes. In this context, the EU-funded DCDP project proposes an innovative and disruptive digital cancer diagnostic platform that uses nanotechnology combined with spatial pattern recognition software to diagnose cancer. This technology will facilitate the identification and analysis of multiple biomarkers at a speed that is not currently possible. It is expected to have a significant impact on the cancer burden for women with endometrial cancer. The project’s aim is to develop the digital cancer diagnostic platform into a fully tested and validated product for adoption by pathology and related services globally.
Objective
Chromition have developed innovative and disruptive digital cancer diagnostic platform. The platform uses Chromition’s innovative Luminspheres™ nanotechnology combined with spatial pattern recognition software to diagnose cancer.
Luminspheres™ are multicoloured fluorescent nanoparticles that are prepared from carbon-based precursors in water at low temperature using our proprietary and environmentally considerate process.
Luminspheres™ bioimaging probes when tethered to biological molecules of interest provide sensitive and non-invasive insight into biological processes and interactions with minimal impact on the system under investigation.
Chromition are working with the Manchester University NHS Foundation Trust (MFT), using the Luminspheres™-antibody biomarker conjugates to stain tissue samples. The tissue samples are then analysed by Chromition’s digital platform, which is able to analyse multiple biomarkers in a short space of time using bespoke spatial pattern recognition software.
Chromition will use Luminspheres™ in Immunohistochemical Staining (IHC) to rapidly identify multiple biomarkers in a single image. The image will then be analysed by innovative software that facilitates fast and autonomous analysis of multiple samples across a clinical cohort.
The development of this technology will enable the identification and analysis of multiple biomarkers at a speed not currently possible using existing technology and relying on human sight.
The success of this project has the potential to transform the way clinical pathology is practiced.
In this project the platform will be used to identify multiple cancer biomarkers in tissue samples from women with endometrial cancers.
Utilising the Chromition method firstly for the identification of endometrial cancers, and using the results to tailor medical intervention, will have a significant impact on the cancer burden for women in the EU and globally.
Fields of science
- medical and health sciencesclinical medicineoncology
- medical and health sciencesbasic medicinepathology
- medical and health scienceshealth sciencespersonalized medicine
- natural sciencescomputer and information sciencesartificial intelligencepattern recognition
- medical and health sciencesbasic medicineimmunologyimmunotherapy
Programme(s)
Funding Scheme
SME-1 - SME instrument phase 1Coordinator
SK4 3GN STOCKPORT
United Kingdom
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.